Medical School · Year 3 · Psychiatry · includes a quiz and discussion video

Seminar 12: Neurocognitive Disorders

Year 3: Psychiatry Clerkship

Learning Objectives

By the end of this seminar, students will be able to:

1. Differentiate delirium from dementia
2. Recognize major and mild neurocognitive disorders
3. Identify specific dementia subtypes
4. Evaluate cognitive impairment
5. Apply treatment and management strategies
6. Address behavioral symptoms in dementia

Seminar Outline

I. Overview of Neurocognitive Disorders

The DSM-5 classification of neurocognitive disorders encompasses conditions characterized by acquired deficits in cognitive function that represent a decline from a previous level of performance. Delirium is defined as an acute disturbance in attention and awareness, developing over a short period and fluctuating in severity, accompanied by an additional disturbance in cognition. Major neurocognitive disorder, the term that has replaced dementia in DSM-5 though dementia remains in common clinical use, involves significant cognitive decline from a previous level of performance in one or more cognitive domains that interferes with independence in everyday activities. Mild neurocognitive disorder represents a less severe syndrome involving modest cognitive decline that does not interfere with independence but may require compensatory strategies. This classification acknowledges the spectrum of cognitive impairment from minimal deficits through severe dementia.

The cognitive domains assessed in neurocognitive disorders provide a framework for characterizing the pattern of impairment and inferring the likely underlying etiology. Complex attention encompasses sustained attention, divided attention, selective attention, and processing speed, and is prominently affected in delirium and in some dementias particularly vascular. Executive function includes planning, decision-making, working memory, mental flexibility, and response to feedback, and is characteristically impaired in frontotemporal dementia. Learning and memory involves immediate, recent, and remote memory, with recent memory particularly affected in Alzheimer disease. Language encompasses expressive and receptive language, naming, and fluency, and may be preferentially affected in primary progressive aphasia variants of frontotemporal dementia. Perceptual-motor function includes visual perception, visuoconstructional abilities, and praxis. Social cognition involves recognition of emotions and theory of mind.

The etiological subtypes of major neurocognitive disorder include numerous conditions that cause progressive cognitive decline through different pathophysiological mechanisms. Alzheimer disease is the most common cause, accounting for 60-80% of dementia cases, characterized by insidious onset and gradual progression with early memory impairment. Vascular neurocognitive disorder results from cerebrovascular disease and may present with step-wise decline or gradual progression depending on the pattern of vascular injury. Lewy body disease involves visual hallucinations, parkinsonism, and fluctuating cognition. Frontotemporal dementia encompasses conditions primarily affecting the frontal and temporal lobes, presenting with behavioral changes or language impairment. Other etiologies include Parkinson disease dementia, traumatic brain injury, HIV-associated neurocognitive disorder, prion diseases, and substance-induced conditions.

Epidemiological data on neurocognitive disorders reveal a significant and growing public health burden. The prevalence of dementia doubles approximately every five years after age 65, affecting an estimated 5-10% of individuals over age 65 and rising to 30-50% in those over 85. Alzheimer disease accounts for the majority of cases, followed by vascular cognitive impairment and Lewy body disease. In the United States, over 5 million people are living with dementia, with projections suggesting this number will nearly triple by 2050 as the population ages. Risk factors include advancing age as the strongest factor, genetic factors including APOE epsilon 4 allele for Alzheimer disease, cardiovascular risk factors, lower educational attainment, head injury, and potentially modifiable lifestyle factors including physical inactivity and social isolation.

<image>Panel A: DSM-5 neurocognitive disorder classification showing delirium (acute, fluctuating), major NCD (significant decline, impaired independence), and mild NCD (modest decline, preserved independence) with relationships and progression pathways. Panel B: Six cognitive domains illustrated with examples of tasks affected in each: complex attention (digit span), executive function (planning), learning/memory (word list recall), language (naming), perceptual-motor (copying figures), and social cognition (emotion recognition). Panel C: Etiological pie chart showing proportion of dementias by cause: Alzheimer (60-80%), vascular, Lewy body, frontotemporal, and other, with key distinguishing features for each listed. Panel D: Epidemiological trends showing age-specific prevalence rates doubling every 5 years after 65, with projected number of affected individuals over coming decades.</image>

II. Delirium

Delirium is diagnosed according to DSM-5 criteria that capture its acute, fluctuating nature and the characteristic disturbance in attention and awareness. Criterion A requires a disturbance in attention, manifested as reduced ability to direct, focus, sustain, and shift attention, and awareness, meaning reduced orientation to the environment. Criterion B specifies that the disturbance develops over a short period of time, usually hours to a few days, represents a change from baseline attention and awareness, and tends to fluctuate in severity during the course of the day. Criterion C requires an additional disturbance in cognition such as memory deficit, disorientation, language, visuospatial ability, or perception. Criterion D indicates that the disturbances in Criteria A and C are not better explained by a pre-existing, established, or evolving neurocognitive disorder and do not occur in the context of a severely reduced level of arousal such as coma. Criterion E requires evidence from the history, physical examination, or laboratory findings that the disturbance is a direct physiological consequence of another medical condition, substance intoxication or withdrawal, or exposure to a toxin, or is due to multiple etiologies.

The clinical features of delirium extend beyond the diagnostic criteria and help clinicians recognize this common but frequently missed condition. Attention is the core affected domain, with patients unable to maintain focus on conversation or examination, easily distracted by irrelevant stimuli, and requiring repeated redirection. Orientation is typically impaired, with disorientation to time most common, followed by place, and rarely person in severe cases. The sleep-wake cycle is disrupted, often with daytime somnolence and nighttime agitation, a pattern sometimes called sundowning. Onset over hours to days distinguishes delirium from dementia, which develops over months to years. The hallmark fluctuating course means that patients may appear relatively lucid during one assessment and profoundly confused hours later, which can mislead clinicians who see only part of the clinical picture. Duration is typically days to weeks, though persistent delirium may continue for months in some cases.

The clinical subtypes of delirium have implications for recognition and management. Hyperactive delirium presents with agitation, restlessness, hallucinations (typically visual), combativeness, and psychomotor hyperactivity, making it the most easily recognized form. Hypoactive delirium, in contrast, presents with lethargy, reduced psychomotor activity, decreased alertness, and quiet confusion, often missed because patients do not create the disruption that brings them to attention. Mixed delirium alternates between hyperactive and hypoactive states, sometimes within hours. Studies consistently show that hypoactive delirium is more common than hyperactive but less frequently recognized, leading to delayed diagnosis and treatment. Both subtypes carry significant morbidity and mortality, though some data suggest hypoactive delirium may have worse outcomes, possibly related to delayed recognition.

The causes of delirium are numerous, with the mnemonic I WATCH DEATH providing a useful framework for systematic evaluation. Infection is among the most common causes, particularly urinary tract infection and pneumonia in elderly patients, where infection may present with delirium as the primary manifestation rather than typical symptoms. Withdrawal from alcohol or sedative-hypnotics must be considered in appropriate clinical contexts. Acute metabolic disturbances including electrolyte abnormalities, hypoglycemia, hyperglycemia, uremia, and hepatic encephalopathy cause delirium through direct effects on brain function. Trauma to the head can produce delirium through concussion, subdural hematoma, or other mechanisms. CNS pathology including stroke, seizure, and meningitis should be considered. Hypoxia from any cause affects brain function early. Deficiencies particularly of thiamine and vitamin B12 can present with delirium. Endocrine disorders including thyroid disease and adrenal dysfunction may manifest with confusion. Acute vascular events including myocardial infarction can trigger delirium. Toxins and drugs are among the most common causes, with anticholinergic medications, opioids, benzodiazepines, and polypharmacy prominent among culprits. Heavy metals are rarely implicated but should be considered in appropriate occupational or environmental contexts.

<image>Panel A: DSM-5 diagnostic criteria for delirium shown as flowchart: attention/awareness disturbance plus acute onset/fluctuating course plus additional cognitive disturbance, not explained by other NCD, and evidence of medical/substance etiology. Panel B: Clinical features comparison between delirium subtypes: hyperactive (agitation, hallucinations, combativeness), hypoactive (lethargy, quiet confusion, reduced activity), and mixed (alternating between states), with recognition challenges for each noted. Panel C: Fluctuating course illustrated as a graph showing cognitive function varying significantly over a 24-hour period, with lucid intervals and periods of profound confusion marked. Panel D: I WATCH DEATH mnemonic expanded with specific examples for each letter (Infection - UTI, pneumonia; Withdrawal - alcohol, benzos; etc.) organized as a diagnostic checklist.</image>

III. Delirium Management

The evaluation of delirium requires a systematic approach to identify the underlying cause while simultaneously providing supportive care. History should focus on baseline cognitive status, timeline of mental status changes, current medications including recent additions or dose changes, substance use history, and symptoms suggesting specific etiologies. Physical examination should assess vital signs, look for sources of infection, evaluate for focal neurological signs, and identify stigmata of organ failure or specific conditions. Laboratory workup should be comprehensive, typically including complete blood count to assess for infection or anemia; comprehensive metabolic panel for electrolyte abnormalities, glucose, renal function, and liver function; urinalysis to evaluate for urinary tract infection; thyroid function tests; and additional studies as indicated by the clinical presentation. Imaging with head CT is indicated when stroke, hemorrhage, mass lesion, or other structural pathology is suspected. Other studies including electrocardiogram, chest radiograph, blood cultures, and lumbar puncture may be warranted based on clinical findings.

Screening tools facilitate recognition of delirium, which is frequently missed even in hospitalized patients. The Confusion Assessment Method is the most widely used and validated screening tool, assessing four features: acute onset and fluctuating course, inattention, disorganized thinking, and altered level of consciousness, with positive screening requiring features 1 and 2 plus either 3 or 4. The CAM-ICU has been adapted for use in critically ill and intubated patients, using nonverbal assessment methods. The 4AT is a rapid screening tool that can be completed in less than two minutes, assessing alertness, orientation, attention, and acuity of change. These screening tools are designed for detection, not diagnosis; positive screens should prompt comprehensive evaluation. Regular screening in high-risk populations, particularly hospitalized elderly patients, improves detection rates.

The CAM criteria operationalize the key features of delirium in a format suitable for clinical screening. Feature 1, acute onset and fluctuating course, is assessed by asking whether there was an acute change in mental status from baseline and whether the abnormal behavior fluctuates during the day. Feature 2, inattention, can be assessed by asking the patient to recite the days of the week backward, count backward from 20 to 1, or perform other attention-demanding tasks. Feature 3, disorganized thinking, is evidenced by rambling or incoherent speech, unclear or illogical flow of ideas, or unpredictable switching between subjects. Feature 4, altered level of consciousness, is anything other than alert, including hyperalert, lethargic, stuporous, or comatose. The diagnosis of delirium by CAM requires the presence of features 1 and 2 plus either feature 3 or 4.

Treatment of delirium prioritizes identification and correction of the underlying cause, with symptomatic management playing a supportive role. Identifying and treating the etiology is the primary intervention, whether that involves treating infection with antibiotics, correcting electrolyte abnormalities, discontinuing offending medications, or managing other precipitating conditions. Non-pharmacological interventions are first-line for managing delirium symptoms and include frequent reorientation with clocks, calendars, and familiar objects; maintenance of sleep-wake cycle; provision of hearing aids and glasses to optimize sensory function; early mobilization when medically appropriate; avoidance of physical restraints which typically worsen agitation; presence of family members to provide reassurance; and environmental modifications to reduce overstimulation. Pharmacological treatment is reserved for patients who are dangerous to themselves or others or who have distress that cannot be managed by non-pharmacological means. Antipsychotics, particularly haloperidol, are most commonly used, with monitoring for QTc prolongation; atypical antipsychotics including quetiapine, olanzapine, and risperidone are alternatives. Benzodiazepines should be avoided except in alcohol or benzodiazepine withdrawal delirium, where they are the treatment of choice.

<image>Panel A: Delirium evaluation algorithm showing history (timeline, medications, substance use), physical examination (vital signs, infection source, neurological exam), laboratory workup (CBC, CMP, UA, TSH), and imaging/additional studies as indicated by clinical suspicion. Panel B: CAM screening tool with four features visually depicted: Feature 1 (acute onset, fluctuation - timeline graph), Feature 2 (inattention - patient unable to focus), Feature 3 (disorganized thinking - jumbled speech bubbles), Feature 4 (altered consciousness - spectrum from hyperalert to comatose), with diagnostic algorithm showing required combinations. Panel C: Non-pharmacological interventions illustrated: reorientation (clock, calendar), sensory optimization (glasses, hearing aids), sleep-wake maintenance (dark room at night), mobilization (patient walking), family presence (visitors), and environmental modification (reduced noise). Panel D: Pharmacological treatment decision tree showing antipsychotics for agitation/distress (haloperidol with QTc monitoring, atypicals as alternatives) versus benzodiazepines specifically for alcohol/benzo withdrawal delirium.</image>

IV. Alzheimer's Disease

The pathophysiology of Alzheimer disease involves characteristic changes in brain structure and function that develop years before clinical symptoms become apparent. Amyloid plaques are extracellular deposits of beta-amyloid protein, a cleavage product of amyloid precursor protein, that accumulate throughout the cerebral cortex and are one of the pathological hallmarks of the disease. Neurofibrillary tangles are intracellular aggregates of hyperphosphorylated tau protein, a microtubule-associated protein that becomes abnormally phosphorylated and forms paired helical filaments within neurons. Neuronal loss is progressive and affects the hippocampus and entorhinal cortex early, explaining the characteristic early memory impairment, then spreads to temporal and parietal association cortices. Cholinergic deficit results from degeneration of cholinergic neurons in the basal forebrain, particularly the nucleus basalis of Meynert, and provides the rationale for treatment with cholinesterase inhibitors. The relationship between amyloid deposition, tau pathology, neuronal death, and cognitive symptoms remains an area of active investigation.

The clinical presentation of Alzheimer disease typically follows a progressive course through recognizable stages, though individual presentations vary. Mild stage Alzheimer disease is characterized by short-term memory loss, with difficulty remembering recent conversations, appointments, and events while remote memories remain relatively preserved; word-finding difficulties may emerge; and patients may get lost in familiar environments. Moderate stage involves progression to disorientation regarding time and place, more severe memory impairment affecting both recent and remote memories, impaired judgment and reasoning, difficulty with instrumental activities of daily living such as managing finances and medications, and emergence of behavioral and psychological symptoms including paranoia, agitation, and wandering. Severe stage Alzheimer disease involves profound memory loss including failure to recognize family members, loss of basic activities of daily living including dressing and hygiene, physical decline including gait impairment and incontinence, and eventual total dependence with death typically from complications such as aspiration pneumonia.

Diagnostic features support the clinical diagnosis of Alzheimer disease and help differentiate it from other causes of dementia. Memory impairment is characteristically early and prominent, with difficulty encoding new information leading to rapid forgetting; patients may ask the same questions repeatedly or forget recent conversations entirely. The onset is insidious, with family members often unable to pinpoint when symptoms began, though they may recognize in retrospect that subtle changes were present for years. The course is gradually progressive, with continuous decline rather than the step-wise deterioration more typical of vascular dementia. Other cognitive domains become affected as the disease progresses, including language with word-finding difficulty and eventually fluent aphasia, visuospatial abilities with difficulty copying figures and getting lost, and executive function with impaired judgment and planning. Neuroimaging with MRI characteristically shows hippocampal atrophy out of proportion to overall brain atrophy, as well as ventricular enlargement and cortical atrophy in temporal and parietal regions. PET imaging shows hypometabolism in temporoparietal regions, and amyloid PET can demonstrate amyloid deposition in the brain.

Risk factors for Alzheimer disease include both modifiable and non-modifiable factors that inform prevention strategies and identify individuals at higher risk. Age is the strongest risk factor, with incidence roughly doubling every five years after age 65. Genetic factors include the APOE epsilon 4 allele, present in about 15% of the population, which increases risk approximately threefold in heterozygotes and twelvefold in homozygotes; rare autosomal dominant mutations in presenilin 1, presenilin 2, or amyloid precursor protein cause early-onset familial Alzheimer disease. Family history of dementia in a first-degree relative increases risk even in the absence of known genetic mutations. Cardiovascular risk factors including hypertension, diabetes, obesity, and hyperlipidemia are associated with increased Alzheimer disease risk, providing a rationale for cardiovascular risk factor management as a prevention strategy. History of traumatic brain injury, particularly repeated concussions, increases risk. Potentially protective factors include higher educational attainment, regular physical exercise, social engagement, and cognitive stimulation, which may build cognitive reserve that delays clinical manifestation of disease.

<image>Panel A: Alzheimer pathology illustration showing brain cross-section with amyloid plaques (extracellular deposits) and neurofibrillary tangles (intracellular tau aggregates), with progression arrows showing spread from hippocampus to cortical areas. Panel B: Clinical staging diagram showing mild (short-term memory loss, word-finding difficulty), moderate (disorientation, behavioral symptoms, IADL impairment), and severe (profound memory loss, basic ADL loss, physical decline) stages with typical duration and functional status at each. Panel C: Diagnostic features including characteristic memory pattern (impaired encoding, rapid forgetting), neuroimaging findings (hippocampal atrophy on MRI, temporoparietal hypometabolism on PET), and CSF biomarkers (low amyloid, high tau). Panel D: Risk factor diagram showing non-modifiable factors (age, genetics, family history) and modifiable factors (cardiovascular risk factors, head injury, education, exercise, social engagement) with relative risk magnitudes indicated.</image>

V. Other Major Dementias

Vascular neurocognitive disorder results from cerebrovascular disease causing cognitive impairment through various mechanisms including large vessel infarcts, small vessel disease, strategic infarcts, and hemorrhagic lesions. The onset may be sudden, particularly following a discrete stroke affecting cognitive regions, or gradual when caused by accumulating small vessel disease. The course is classically described as step-wise, with periods of stability punctuated by acute declines corresponding to new vascular events, though continuous gradual decline also occurs. The pattern of cognitive impairment depends on the location of vascular lesions, but executive dysfunction is often prominent, with relatively preserved memory in some patients distinguishing them from Alzheimer disease. Neuroimaging with MRI reveals white matter hyperintensities, lacunar infarcts, or cortical strokes depending on the type of vascular pathology. Cardiovascular risk factors including hypertension, diabetes, hyperlipidemia, smoking, and atrial fibrillation are typically present and should be managed aggressively to prevent further vascular injury.

Lewy body dementia is characterized by a distinctive clinical syndrome with three core features: visual hallucinations that are typically detailed and well-formed, fluctuating cognition with pronounced variations in attention and alertness, and parkinsonism with rigidity, bradykinesia, and gait abnormalities. Suggestive features that support the diagnosis include REM sleep behavior disorder, in which patients act out dreams due to lack of normal REM atonia, often predating cognitive symptoms by years; severe neuroleptic sensitivity, with marked worsening of parkinsonism and potentially life-threatening reactions to antipsychotic medications; and low dopamine transporter uptake in basal ganglia on SPECT or PET imaging. The timing criterion distinguishes Lewy body dementia from Parkinson disease dementia: in Lewy body dementia, dementia develops before or within one year of parkinsonism, while in Parkinson disease dementia, parkinsonism precedes dementia by more than one year. The visual hallucinations of Lewy body dementia are characteristically detailed images of people or animals, often occurring in the evening, and patients may retain some insight that they are not real. Management requires extreme caution with antipsychotic medications, which can cause severe sensitivity reactions including rigidity, immobility, and death; when antipsychotics are necessary, quetiapine or clozapine are preferred.

Frontotemporal dementia encompasses a group of disorders characterized by progressive degeneration of the frontal and temporal lobes, with distinct clinical syndromes corresponding to the predominant site of pathology. The behavioral variant presents with prominent personality change and behavioral disinhibition, including socially inappropriate behavior, loss of empathy and social cognition, apathy and inertia, compulsive or ritualistic behaviors, and dietary changes including preference for sweets. Primary progressive aphasia variants include semantic dementia with progressive loss of word and object meaning, and progressive nonfluent aphasia with effortful speech production and grammatical errors. Age of onset is typically younger than Alzheimer disease, commonly in the 50s or 60s, though range extends from 40s to 80s. Memory is relatively preserved early in behavioral variant compared to Alzheimer disease, though this distinction may be difficult clinically. Neuroimaging shows frontal and/or temporal atrophy, which may be asymmetric. There are no FDA-approved treatments for frontotemporal dementia, and management focuses on behavioral interventions and treatment of specific symptoms.

Other causes of dementia warrant consideration in the differential diagnosis of cognitive impairment. Parkinson disease dementia develops in a significant proportion of patients with Parkinson disease, typically later in the disease course, with impairments in attention, executive function, and visuospatial abilities. Normal pressure hydrocephalus presents with a classic triad of gait disturbance, urinary incontinence, and dementia, and is potentially reversible with shunting. Creutzfeldt-Jakob disease is a rapidly progressive prion disease with myoclonus, distinctive EEG findings, and elevated 14-3-3 protein in cerebrospinal fluid, typically fatal within one year. HIV-associated neurocognitive disorder occurs in the context of HIV infection, is less common with effective antiretroviral therapy, but remains a concern particularly with medication non-adherence. Alcohol-related dementia and Korsakoff syndrome result from chronic alcohol use and thiamine deficiency, with Korsakoff syndrome characterized by profound anterograde amnesia with relative preservation of other cognitive functions.

<image>Panel A: Vascular dementia features including step-wise decline pattern on timeline graph, neuroimaging showing white matter hyperintensities and lacunar infarcts on MRI, and cardiovascular risk factor list (hypertension, diabetes, hyperlipidemia, smoking, atrial fibrillation). Panel B: Lewy body dementia core features triad (visual hallucinations depicted as detailed figures, fluctuating cognition shown as attention graph, parkinsonism illustrated with gait/movement), plus warning about severe neuroleptic sensitivity with medication caution symbols. Panel C: Frontotemporal dementia variants shown with brain diagrams indicating affected regions: behavioral variant (frontal - disinhibition, apathy), semantic dementia (anterior temporal - word meaning loss), progressive nonfluent aphasia (left frontal - effortful speech), with typical younger age of onset noted. Panel D: Other dementias grid showing Parkinson disease dementia (late in PD course), normal pressure hydrocephalus (triad with potential reversibility), CJD (rapid with myoclonus), HIV-associated (with ART considerations), and alcohol-related (Korsakoff features).</image>

VI. Evaluation of Cognitive Impairment

The clinical history in cognitive impairment evaluation should systematically characterize the onset, course, affected domains, and functional impact of cognitive changes. Onset and course determination includes establishing when symptoms were first noticed, whether onset was sudden or gradual, and whether decline has been progressive, stable, or step-wise. Determining which cognitive domains are affected helps narrow the differential, with early memory impairment suggesting Alzheimer disease, early personality change suggesting frontotemporal dementia, and fluctuating attention suggesting delirium or Lewy body disease. Functional assessment evaluates impact on activities of daily living, distinguishing mild neurocognitive disorder where independence is preserved from major neurocognitive disorder where it is impaired. Behavioral and psychiatric symptoms including depression, apathy, psychosis, agitation, and sleep disturbance should be assessed. Collateral information from family members or caregivers is essential, as patients with dementia often have impaired insight and may underestimate or be unaware of their deficits.

Cognitive testing provides objective measurement of cognitive function and helps characterize the pattern of impairment. The Mini-Mental State Examination is a widely used 30-point screening tool assessing orientation, registration, attention, recall, language, and visuospatial function, with scores below 24 generally considered abnormal in those with at least a high school education. The Montreal Cognitive Assessment is more sensitive than the MMSE for detecting mild cognitive impairment and includes more challenging tasks for attention, executive function, and memory, with scores below 26 considered abnormal. Clock drawing tests visuospatial abilities and executive function, requiring patients to draw a clock face with numbers and set the hands to a specified time. The Mini-Cog combines a three-word recall task with clock drawing for rapid screening. Comprehensive neuropsychological testing provides detailed assessment across multiple cognitive domains and can help differentiate dementia subtypes, establish baseline for monitoring, and assess capacity for specific decisions.

Laboratory workup aims to identify reversible causes of cognitive impairment and assess for conditions that may contribute to or complicate dementia. Standard testing should include complete blood count to assess for anemia; comprehensive metabolic panel for electrolyte abnormalities, renal dysfunction, and hepatic dysfunction; thyroid stimulating hormone to screen for hypothyroidism; vitamin B12 level to identify deficiency; and RPR or VDRL to screen for neurosyphilis. Additional testing based on clinical suspicion may include HIV testing in appropriate risk groups, heavy metal screening if exposure history suggests, and assessment for autoimmune conditions. Lumbar puncture with cerebrospinal fluid analysis may be indicated when inflammatory, infectious, or rapidly progressive conditions are suspected, and CSF amyloid and tau biomarkers can support or refute the diagnosis of Alzheimer disease.

Neuroimaging plays an important role in the evaluation of cognitive impairment, identifying structural abnormalities, characteristic atrophy patterns, and cerebrovascular disease. CT scanning can rule out structural lesions including tumors, subdural hematomas, and normal pressure hydrocephalus, and is often sufficient as an initial study. MRI is preferred when available, providing better resolution for atrophy patterns (hippocampal atrophy in Alzheimer disease, focal frontal/temporal atrophy in frontotemporal dementia), white matter disease, and small vessel ischemic changes. FDG-PET shows metabolic patterns characteristic of different dementias, with temporoparietal hypometabolism in Alzheimer disease and frontal hypometabolism in frontotemporal dementia. Amyloid PET imaging can detect brain amyloid deposition, is increasingly used in clinical practice, and may be particularly useful when Alzheimer disease is suspected but the presentation is atypical. CSF biomarkers, including low amyloid-beta 42 and elevated total tau and phosphorylated tau, support the diagnosis of Alzheimer disease when there is diagnostic uncertainty.

<image>Panel A: Clinical history framework showing domains to assess: onset/course characteristics, affected cognitive domains mapped to differential diagnoses, functional status (IADLs for mild NCD, basic ADLs for major NCD), behavioral symptoms, and importance of collateral information from family. Panel B: Cognitive testing tools comparison showing MMSE (30 points, cutoff 24), MoCA (30 points, cutoff 26, more sensitive for MCI), clock drawing (visuospatial/executive), and Mini-Cog (three-word recall plus clock) with appropriate clinical use for each. Panel C: Laboratory workup panel organized as standard tests (CBC, CMP, TSH, B12, RPR) and additional tests based on clinical suspicion (HIV, heavy metals, autoimmune, lumbar puncture for specific indications). Panel D: Neuroimaging modalities with characteristic findings: CT (structural lesions), MRI (atrophy patterns, white matter disease), FDG-PET (metabolic patterns by dementia type), amyloid PET (amyloid deposition), and CSF biomarkers (amyloid, tau).</image>

VII. Treatment of Dementia

Cholinesterase inhibitors are the first-line pharmacological treatment for Alzheimer disease, working by inhibiting the breakdown of acetylcholine in the synaptic cleft to compensate for the cholinergic deficit caused by degeneration of basal forebrain cholinergic neurons. Donepezil is the most commonly prescribed, given once daily and approved for all stages of Alzheimer disease, with typical dosing of 5 mg initially increased to 10 mg after 4-6 weeks and a 23 mg formulation available for moderate to severe disease. Rivastigmine is available in oral and transdermal patch formulations, with the patch often preferred due to reduced gastrointestinal side effects; it is also approved for Parkinson disease dementia. Galantamine is given twice daily and has both cholinesterase inhibition and nicotinic receptor modulation. The efficacy of cholinesterase inhibitors is modest, with clinical trials showing statistically significant but small improvements in cognitive and global function measures, and these medications do not halt or reverse disease progression but may slow decline and delay functional deterioration. Common side effects are gastrointestinal, including nausea, vomiting, and diarrhea, which often improve with continued use; bradycardia can occur and warrants caution in patients with cardiac conduction abnormalities.

Memantine is an NMDA receptor antagonist approved for moderate to severe Alzheimer disease, working through a different mechanism than cholinesterase inhibitors. The mechanism involves blocking excessive glutamate signaling that may contribute to neuronal injury while allowing normal physiological signaling to continue. Combination therapy with a cholinesterase inhibitor plus memantine is commonly used in moderate to severe disease, with some evidence suggesting additional benefit from combination compared to cholinesterase inhibitor alone. Side effects include confusion, dizziness, and headache, which are generally mild. Dosing begins at 5 mg daily with gradual titration to a target of 10 mg twice daily or 28 mg once daily for the extended-release formulation.

Newer treatments for Alzheimer disease have emerged targeting the amyloid pathology believed to drive the disease. Aducanumab was the first anti-amyloid antibody approved by the FDA, granted accelerated approval in 2021 despite controversy about clinical efficacy, with evidence showing reduction in brain amyloid but conflicting results regarding cognitive benefit. Lecanemab received traditional FDA approval in 2023 after demonstrating modest but statistically significant slowing of cognitive and functional decline in early Alzheimer disease, with effects attributable to amyloid clearance. These medications require baseline amyloid PET or CSF testing to confirm amyloid pathology, carry risk of amyloid-related imaging abnormalities (ARIA) including brain edema and microhemorrhages requiring MRI monitoring, and are most appropriate for early disease stages. Disease-modifying treatments remain a major focus of research, with ongoing trials targeting amyloid, tau, inflammation, and other pathways.

Non-pharmacological interventions are essential components of dementia care that may slow decline and improve quality of life. Cognitive stimulation involves activities designed to engage cognitive abilities, including group programs, puzzles, and meaningful activities, with evidence suggesting modest benefits for cognitive function and well-being. Regular physical exercise has benefits for cognition, physical function, and mood, and may reduce behavioral symptoms. Occupational therapy helps patients and caregivers adapt the environment and activities to maintain function and safety, including simplifying tasks, using memory aids, and modifying the home. Caregiver support is essential given the enormous burden of dementia caregiving. Structured environment with consistent routines reduces confusion and behavioral symptoms. Reality orientation and validation approaches offer different frameworks for interacting with patients about their confusion about time, place, and circumstances.

<image>Panel A: Cholinesterase inhibitors mechanism diagram showing reduced acetylcholine in Alzheimer disease due to cholinergic neuron loss, and medication effects blocking acetylcholinesterase to increase synaptic acetylcholine, with specific medications (donepezil, rivastigmine, galantamine) and their characteristics listed. Panel B: Memantine mechanism showing NMDA receptor blockade of excessive glutamate signaling with preservation of normal signaling, typical dosing titration schedule, and indication for moderate-severe disease in combination with cholinesterase inhibitor. Panel C: Newer anti-amyloid therapies showing aducanumab and lecanemab, amyloid removal mechanism, monitoring requirements (baseline amyloid confirmation, MRI for ARIA), and appropriate patient population (early disease with confirmed amyloid). Panel D: Non-pharmacological interventions illustrated: cognitive stimulation (group activities, puzzles), exercise (walking, physical therapy), occupational therapy (home modifications, memory aids), caregiver support (education, respite), and structured environment (routines, simplified layout).</image>

VIII. Behavioral Symptoms in Dementia

Behavioral and psychological symptoms of dementia affect the vast majority of patients at some point during the disease course and are often more distressing to patients and caregivers than cognitive symptoms. Mood symptoms including depression and apathy are common, with depression affecting up to 50% of patients and apathy, characterized by diminished motivation and initiative, even more prevalent. Psychotic symptoms including delusions, often paranoid in nature with themes of theft, infidelity, or persecution, and hallucinations, typically visual, occur in 30-50% of patients. Agitation and aggression encompass a range of behaviors from verbal outbursts and resistance to care to physical aggression, affecting up to 80% of patients at some point. Sleep disturbances include insomnia, day-night reversal, and sundowning, in which confusion and agitation worsen in the evening and nighttime hours. Other symptoms include disinhibition, wandering, repetitive behaviors, and hoarding.

The approach to behavioral symptoms in dementia should follow a systematic process that addresses underlying causes before resorting to pharmacological management. Ruling out medical causes is the first step, as urinary tract infection, constipation, pain, and other medical conditions commonly trigger behavioral changes in patients who cannot articulate their discomfort. Reviewing medications is essential, as anticholinergic medications and polypharmacy frequently contribute to confusion and behavioral disturbance. Identifying triggers involves looking for environmental factors, unmet needs such as hunger, thirst, or need for toileting, and patterns in when behavioral symptoms occur. Non-pharmacological interventions are the preferred first-line approach, including addressing unmet needs, modifying the environment, providing appropriate stimulation, and training caregivers in communication and behavioral management strategies.

Non-pharmacological interventions for behavioral symptoms in dementia have evidence supporting their efficacy and should be tried before medications in most situations. Music therapy can reduce agitation and improve mood, with personalized playlists of familiar songs often most effective. Validation therapy involves acknowledging and accepting the patient's emotional experience rather than correcting their misperceptions, which can reduce frustration and improve the caregiving relationship. Redirection and distraction techniques involve gently steering the patient away from distressing topics or activities toward more pleasant ones. Sensory approaches provide appropriate stimulation while avoiding overstimulation that can worsen agitation. Environmental modifications include reducing noise and crowding, improving lighting, and creating safe spaces for wandering. Caregiver training in communication strategies, including speaking slowly and simply, using yes-no questions, and giving one-step instructions, can prevent and de-escalate behavioral disturbances.

Pharmacological management of behavioral symptoms in dementia requires careful consideration of risks and benefits, with particular attention to the increased risks of antipsychotic medications in this population. For depression, SSRIs such as sertraline and citalopram are first-line, with evidence supporting their efficacy; mirtazapine is an alternative when sedation or appetite stimulation is desired. For agitation and aggression, non-pharmacological approaches should be attempted first; when medications are necessary, low-dose atypical antipsychotics such as risperidone, olanzapine, or quetiapine may be used with awareness of the FDA black box warning regarding increased mortality risk in elderly patients with dementia. For psychosis with distressing hallucinations or dangerous delusions, low-dose atypical antipsychotics may be warranted despite the mortality risk when symptoms are severe. For sleep disturbances, trazodone is often used; melatonin may help with circadian rhythm disruption; benzodiazepines should be avoided due to risks of falls, confusion, and paradoxical disinhibition. The critical principle is that antipsychotics increase mortality in patients with dementia through stroke, cardiac events, and infection, and should be used only when benefits clearly outweigh risks, at the lowest effective dose, and with regular reassessment of continued need.

<image>Panel A: BPSD prevalence chart showing common behavioral and psychological symptoms of dementia (depression, apathy, agitation, psychosis, sleep disturbance) with approximate frequency and typical characteristics of each. Panel B: Systematic approach flowchart: rule out medical causes (infection, pain, constipation), review medications (anticholinergics, polypharmacy), identify triggers (environmental, unmet needs), then implement non-pharmacological interventions before considering medications. Panel C: Non-pharmacological interventions illustrated: music therapy (headphones with familiar songs), validation therapy (acknowledging emotions), redirection (gentle steering to pleasant activity), environmental modification (calm, well-lit space), and caregiver communication training. Panel D: Pharmacological management table showing target symptoms (depression, agitation, psychosis, sleep), medications (SSRIs, antipsychotics, trazodone), and risk considerations, with prominent black box warning about antipsychotic mortality risk in dementia.</image>

IX. Mild Cognitive Impairment

Mild cognitive impairment represents a clinical syndrome characterized by cognitive decline that is greater than expected for normal aging but does not meet criteria for dementia, with preserved independence in daily functioning. The diagnostic criteria require concern regarding a change in cognition, typically reported by the patient, a knowledgeable informant, or a clinician; objective impairment in one or more cognitive domains demonstrated on testing, usually defined as performance 1 to 1.5 standard deviations below age and education norms; preservation of independence in functional abilities, meaning the person may take longer or be less efficient but can still perform everyday tasks; and not meeting criteria for dementia or major neurocognitive disorder. This concept captures the transitional state between normal cognition and dementia in which intervention might prevent or delay progression.

The classification of mild cognitive impairment into subtypes helps predict the likelihood and type of progression to dementia. Amnestic MCI involves predominantly memory impairment and is considered most likely to progress to Alzheimer disease dementia. Non-amnestic MCI involves impairment in cognitive domains other than memory, such as attention, executive function, language, or visuospatial abilities, and may progress to frontotemporal dementia, Lewy body dementia, or vascular dementia depending on the specific pattern. Single-domain MCI involves impairment in only one cognitive area, while multiple-domain MCI involves impairment in more than one. Amnestic multiple-domain MCI carries higher risk of progression to Alzheimer disease than single-domain amnestic MCI.

The prognosis of mild cognitive impairment is variable, with outcomes including progression to dementia, stability, or reversion to normal cognition. Conversion to dementia occurs at an estimated rate of 10-15% per year in clinical settings, though rates in community samples are lower. Some individuals with MCI remain stable over years, while others improve and no longer meet MCI criteria on follow-up testing. Risk factors for progression to Alzheimer disease include the presence of APOE epsilon 4 allele, positive amyloid biomarkers on PET or CSF testing, baseline severity of impairment, and presence of neuropsychiatric symptoms. The heterogeneity of outcomes underscores the importance of longitudinal follow-up and the current inability to predict with certainty which individuals will progress.

Management of mild cognitive impairment focuses on risk factor modification, monitoring, and preparation for possible progression while avoiding premature imposition of the dementia label. Regular monitoring with periodic reassessment of cognitive function and functional status, typically every 6-12 months, allows timely detection of progression. Cardiovascular risk factor management including treatment of hypertension, diabetes, and hyperlipidemia may reduce risk of progression, particularly to vascular dementia. Physical exercise has evidence supporting cognitive benefits and should be encouraged. Cognitive engagement through social activities, intellectually stimulating pursuits, and cognitive training may help maintain function, though evidence for preventing progression is limited. No medications are FDA-approved for mild cognitive impairment or prevention of progression to dementia; cholinesterase inhibitors have been studied but have not shown benefit for MCI.

<image>Panel A: MCI diagnostic criteria shown as checklist: cognitive concern (by patient, informant, or clinician), objective impairment on testing (1-1.5 SD below norms), preserved independence (may use compensatory strategies), not meeting dementia criteria. Panel B: MCI subtypes displayed as a grid: amnestic versus non-amnestic on one axis, single-domain versus multiple-domain on the other, with arrows indicating likely progression pathways (amnestic to AD, non-amnestic to FTD/LBD/VaD). Panel C: Prognosis outcomes pie chart showing approximate proportions of progression to dementia (15%/year), stability, and reversion to normal, with risk factors for progression (APOE4, positive amyloid, baseline severity, neuropsychiatric symptoms) listed. Panel D: Management approach showing regular monitoring (cognitive testing timeline), risk factor modification (blood pressure, glucose, lipids), lifestyle interventions (exercise, cognitive engagement, social activity), and notation that no medications are approved for MCI.</image>

X. Caregiver Support and End-of-Life

Caregiver burden in dementia is substantial and has significant implications for caregiver health, patient outcomes, and healthcare utilization. The prevalence of significant caregiver burden approaches 80% among those caring for persons with dementia. Depression affects 30-50% of dementia caregivers, compared to 5-10% of age-matched non-caregivers. Physical health may decline due to stress, disrupted sleep, and neglect of self-care. Social isolation commonly develops as caregiving demands consume time and energy. Financial burden results from direct costs of care, lost income from reduced work, and unpaid caregiving labor. Caregiver burden predicts earlier nursing home placement, and addressing caregiver needs can delay institutionalization and improve outcomes for both caregiver and patient.

Support resources for caregivers provide essential assistance in managing the demands of dementia caregiving. Respite care provides temporary relief from caregiving duties, allowing caregivers time for self-care, appointments, or simply rest, and can be provided by adult day programs, in-home respite workers, or short-term residential facilities. Support groups offered through organizations such as the Alzheimer's Association connect caregivers with others facing similar challenges, providing emotional support, practical advice, and reduced isolation. Education about the disease, its progression, behavioral symptoms, and management strategies helps caregivers understand what to expect and how to respond effectively. Home health services can provide skilled nursing, personal care assistance, and therapies that reduce caregiver burden. Adult day programs offer structured activities and supervision during the day, providing stimulation for patients and respite for caregivers.

Legal and safety issues require proactive planning and ongoing attention as dementia progresses. Driving safety should be assessed early and reassessed periodically, with driving cessation recommended when dementia has progressed to the point of unsafe operation; resources exist for objective driving evaluation when clinical judgment is uncertain. Firearm safety requires removing access to weapons, which become dangerous when judgment and impulse control are impaired. Financial management should be addressed early through power of attorney while the patient has capacity to designate an agent; financial exploitation is common and monitoring for unusual transactions is important. Wandering poses risks of injury and exposure, and can be addressed through door alarms, identification bracelets, and GPS tracking devices. Advance directives including healthcare proxy designation and documentation of wishes regarding aggressive interventions should be completed while the patient can still participate in these decisions.

End-of-life care in dementia requires thoughtful consideration of goals of care and appropriate interventions as the disease progresses to its terminal stages. Early goals of care discussions allow patients to express their values and preferences while they retain capacity, and these conversations should be revisited as the disease progresses. Palliative care focuses on comfort, symptom management, and quality of life, and can be introduced at any disease stage alongside disease-directed treatments. Hospice care is appropriate when prognosis is six months or less, which can be difficult to determine in dementia, and provides a supportive framework for end-of-life care including family support and bereavement services. Feeding tubes are generally not recommended in advanced dementia based on evidence that they do not prevent aspiration pneumonia, prolong survival, or improve comfort; careful hand feeding is the preferred approach. Dignity should be maintained throughout the disease course, with person-centered care that respects the individual's identity and history even as cognitive abilities decline.

<image>Panel A: Caregiver burden data visualization showing prevalence of burden, depression rates among caregivers versus non-caregivers, and domains affected (physical health, mental health, social isolation, financial strain) with impact indicators. Panel B: Support resources illustration showing respite care options (adult day program, in-home respite, short-term residential), support groups, caregiver education, home health services, and Alzheimer's Association resources with contact information. Panel C: Safety and legal planning checklist: driving evaluation and cessation planning, firearm removal, financial power of attorney, wandering prevention measures (alarms, ID bracelet, GPS), and advance directive completion timeline relative to disease progression. Panel D: End-of-life care framework showing early goals-of-care discussions (while capacity exists), palliative care introduction (any stage), hospice criteria for dementia, feeding tube recommendation against, and dignity-focused person-centered care principles.</image>

Summary

• Delirium is an acute, fluctuating disturbance in attention and cognition; it is a medical emergency requiring identification and treatment of the underlying cause
• Delirium subtypes include hyperactive (agitation, obvious), hypoactive (lethargy, easily missed), and mixed; all carry significant morbidity and mortality
• Major neurocognitive disorder (dementia) involves significant cognitive decline that impairs independence in daily activities
• Alzheimer disease is the most common cause of dementia, characterized by insidious onset, gradual progression, early prominent memory impairment, and pathological findings of amyloid plaques and neurofibrillary tangles
• Vascular neurocognitive disorder shows step-wise decline, association with cardiovascular risk factors, and executive dysfunction; management includes aggressive risk factor control
• Lewy body dementia is characterized by visual hallucinations, fluctuating cognition, parkinsonism, and REM sleep behavior disorder; antipsychotics must be avoided or used with extreme caution due to severe neuroleptic sensitivity
• Frontotemporal dementia presents with behavioral changes (disinhibition, apathy) or language impairment; onset is typically younger than Alzheimer disease
• Cognitive evaluation includes standardized testing (MoCA is more sensitive than MMSE), laboratory workup (TSH, B12 to identify reversible causes), and neuroimaging (MRI for atrophy patterns)
• Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) provide modest symptomatic benefit; memantine is added for moderate-severe disease
• Behavioral symptoms in dementia: non-pharmacological approaches are first-line; antipsychotics carry black box warning for increased mortality in dementia and should be used only when benefits clearly outweigh risks

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown